Loading interface...

Jakavi 20 mg Tablet

Manufactured byNOVARTIS INDIA LTD
ContainsRuxolitinib
Description

Jakavi 20 mg Tablet is an anticancer medicine that is used to treat Polycythemia Vera (a type of blood cancer) and Myelofibrosis (a condition of the bone marrow where it becomes unable to produce blood cells). This medicine is not recommended for use in patients below 18 years of age.

How will this medicine affect me?

Consult top doctors online and get an answer now
Chat now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now

Side effects

Major & minor side effects for Jakavi 20 mg Tablet

  • Blood in the urine or stools
  • Black or tarry stools
  • Bleeding gums
  • Bruising
  • Fever
  • Difficult or painful urination
  • Shortness of breath
  • Unusual tiredness or weakness

Uses of Jakavi 20 mg Tablet

What is it prescribed for?

  • Myelofibrosis
  • Polycythemia Vera
Read More
Concerns

Commonly asked questions

  • Onset of action
    The peak effect of this medicine can be observed within 1-2 hours of administration of the dose.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to Ruxolitinib or any other inactive ingredient present along with it.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
General warnings

Infections

Use of this medicine may affect the immune system making you susceptible to opportunistic infections from a wide variety of pathogens. It is advised to not use this medicine during an active infection. Use of this medicine should be discontinued after consulting the doctor if a serious infection develops. There may also risk of tuberculosis and hepatitis B reactivation.

Bonemarrow suppression

This medicine may cause bone marrow suppression which in turn lowers the white blood cell count (neutrophils) and platelets. Close monitoring of blood cell count is necessary. The baseline of the blood cell count should be obtained before initiation of the treatment. Do not start the treatment if the counts are less.

Lipid elevations

Use of this medicine may increase the levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Use of this medicine is advised with caution in patients with lipid level abnormalities. Appropriate dose adjustments and frequent clinical monitoring are advised.

Non-Melanoma Skin Cancer

This medicine may increase the risk of non-melanoma skin cancer including basal cell, squamous cell, and Merkel cell carcinoma. Frequent skin examinations are recommended while on treatment with this medicine.

Progressive multifocal leukoencephalopathy

This medicine may increase the risk of Progressive multifocal leukoencephalopathy which is a serious viral infection of the brain. Frequent examinations are recommended while on treatment with this medicine.

Withdrawal effects

It is observed that symptoms of Myelofibrosis may return over a period of approximately one week on interruption or discontinuation of this medicine. Instead of abrupt discontinuation, gradual tapering of the dose may be considered.

Driving or Operating machinery

Use of this medicine may cause blurred vision or dizziness in some patients. It is advised that you do not perform any activities such as driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Use in Children

This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.

Missed Dose

Administer the missed dose as soon as you remember. If it is almost time for the next scheduled dose then the missed dose can be skipped. Do not double the dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Live attenuated vaccines and related products

Etanercept

Adalimumab

Clozapine

Ritonavir

Disease interactions

Infections

Use of this medicine may cause serious and life-threatening infections caused by a wide variety of pathogens. Hence, treatment with this medicine should not be initiated in a patient with an active infection. While taking this medicine, any signs and symptoms of an infection like fever, chills, sore throat, diarrhea etc should be reported to the doctor immediately. An alternative treatment option should be considered in some cases based on the clinical condition.

Lung Toxicity

This medicine should be used with caution in patients with a history of interstitial lung disease presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation due to the increased risk of the lung toxicity. Appropriate dose adjustments and frequent clinical monitoring are advised in such cases. Replacement with a suitable alternative may be required in some cases based on the clinical condition.

Low blood cell count

This medicine should be used with caution in patients with a low blood cell count due to the increased risk of worsening of the patient's condition. Regular monitoring of the complete blood count is recommended until the dose is stabilized. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Liver Disease

This medicine should be used with caution in patients with impaired liver function since it may worsen the condition. Regular monitoring of the liver function tests is recommended while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Hepatitis B

This medicine should be used with caution in patients with a history of hepatitis B infection. It is recommended to monitor patients with evidence of current or prior hepatitis B infection for signs and symptoms of reactivation. Appropriate dose adjustments and frequent clinical monitoring are advised while receiving this medicine. An alternative treatment option should be considered in some cases based on the clinical condition.

Lipid elevations

Use of this medicine may increase the levels of total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Hence, it is advised to use this medicine with caution in patients with lipid abnormalities. Regular monitoring of the lipid levels is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Kidney Disease

This medicine should be used with caution in patients with impaired kidney function since it may worsen the condition. Regular monitoring of the kidney function tests is recommended while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Tuberculosis

This medicine should be used with extreme caution in patients who have previously been treated for latent or active tuberculosis. Anti-tuberculosis therapy should be initiated prior to therapy with this medicine if an active infection is confirmed. Appropriate tests should be conducted for the presence of latent tuberculosis in patients. An alternative treatment option should be considered in some cases based on the clinical condition.
Food interactions
Avoid grapefruit or grapefruit juice consumption during treatment with this medicine since it may increase the risk of side effects that affect bone marrow function, resulting in low numbers of different types of blood cells. Report any symptoms such as paleness, fatigue, dizziness, fainting, unusual bleeding or bruising, fever, chills, sore throat, body aches, or other flu-like symptoms to your doctor immediately. Appropriate dose adjustments and frequent clinical monitoring are advised.
Lab interactions
Information not available.
Take this medicine exactly as prescribed by the doctor. Do not take in larger or smaller quantities than recommended. Take this medicine with or without food. You may require frequent blood tests and lipid profile while taking this medicine. You may also require frequent followups with your doctor to check the progress of treatment. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine works by blocking certain enzymes responsible for blood cell production.
Legal Status

Approved

Approved

Approved

Approved

Classification

Category

Multikinase inhibitors, Antineoplastics

Schedule

Schedule H

[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 24 December 2018]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1c82580-87ae-11e0-bc84-0002a5d5c51b

[Internet]. Medicines.org.uk. 2018 [cited 24 December 2018]. Available from:

https://www.medicines.org.uk/emc/product/7786/smpc

Ruxolitinib - DrugBank [Internet]. Drugbank.ca. 2018 [cited 24 December 2018]. Available from:

https://www.drugbank.ca/drugs/DB08877

[Internet]. Ebs.tga.gov.au. 2018 [cited 24 December 2018]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01918-1
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 31 Jan 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.